Remove 2013 Remove Competition Remove Prescription
article thumbnail

Sorry, the Inflation Bill won’t lower healthcare costs

World of DTC Marketing

It’s no wonder that voters consistently rank bringing down prescription drug prices and other measures to reduce the cost of care as among Congress’ top priorities. Congress rightly chose to negioate drug prices for Medicare, but prescription drugs are only 10-12% of every healthcare dollar we spend.

article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. 136 (2013), [link] opinions/12pdf/12-416_m5n0.pdf. 1435 (“Affordable Prescriptions for Patients Act of 2021”), [link] gov/bill/117th-congress/senate-bill/1435/text; H.R. Actavis, 570 U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

THEPM360TRAILBLAZER AWARD WINNER – Lifetime Achievement Award – Adam Schechter, CEO and Chairman, Labcorp

PM360

Prior to that, he was named Lead Independent Director in 2019 after serving as a director of the company since 2013. You have to understand the marketplace around you…your competition, your blue space of where you can grow,” Adam said. Adam became CEO of Labcorp in 2019 and Chairman of the Board in 2020.

Ethics 59
article thumbnail

5 Core Tenets of HCP-focused Point-of-Care Marketing

PM360

Because nearly all prescriptions are now written electronically. The Point of Care Marketing Association (POCMA) is the Go-to Source for POC Education/Advocacy Founded in 2013, POCMA supports the POC channel through education and advocacy. And to do that in today’s digital age, you’ve got to think “EHR.”

article thumbnail

Fixed-dose combination: Considerations for design, formulation, manufacturing and analysis

Pharmaceutical Technology

Understanding both the significant competitive advantages that FDC products can offer, and the difficulties and potential pitfalls associated with development and manufacturing of FDC drugs in oral solid dosage forms is a critical first step for companies exploring this approach. More FDC products flowing into pharma pipelines.